Daratumumab Maintenance Improves Survival and Depth of Response in Multiple MyelomaRifkin, Robert M.Journal of Oncology Navigation & Survivorship
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
The regimen is comprised of daratumumab combined with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) induction and consolidation treatment, autologous stem cell transplant (ASCT), and lenalidomide maintenance therapy. “We are committed to changing the course of multiple ...
“Daratumumab plus CyBorD induction followed by monthly daratumumab monotherapy maintenance attained deep and durable responses in patients with newly diagnosed or relapsed myeloma,” Robert M. Rifkin, MD, FACP, of the US Oncology Research Network, Rocky Mountains Cancer Centers, in Denver, ...
When the study was designed, there was not as much informationavailable as there is now regarding the role of maintenance therapy in myeloma, the duration that maintenance should be offered, and the optimal dosing frequency schedule during t...
Darzalex Faspro plus VRd was approved by the FDA for induction and consolidation in newly diagnosed multiple myeloma eligible for ASCT. Subcutaneous Daratumumab Plus VRd Receives FDA Approval for Multiple Myeloma Daratumumab and hyaluronidase-fihj (Darzalex Faspro) was approved by the FDA in com...
Background: The combination of a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and dexamethasone is the current standard induction therapy for myeloma. Daratumumab (Dara), a monoclonal antibody directed against CD38, is highly effective in treating myeloma and improves response rates and...
For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival. These findings we...
Multiple myeloma is a proliferative disorder of plasma cells in the bone marrow with excessive monoclonal protein production. Despite the evolution of multiple drugs and management strategies including maintenance and autologous stem cell transplantation, the long-term results still remain undesirable. Those...